GlaxoSmithKline (LON:GSK) had its price objective boosted by Kepler Capital Markets from GBX 1,440 ($18.82) to GBX 1,540 ($20.12) in a research note published on Tuesday morning, Borsen Zeitung reports. They currently have a hold rating on the stock.
Several other research analysts have also recently weighed in on GSK. Liberum Capital reissued a hold rating on shares of GlaxoSmithKline in a research report on Wednesday, March 20th. UBS Group reissued a neutral rating and issued a GBX 1,650 ($21.56) price objective on shares of GlaxoSmithKline in a research report on Thursday, April 4th. Shore Capital reissued a hold rating on shares of GlaxoSmithKline in a research report on Thursday, May 2nd. Jefferies Financial Group reissued a buy rating on shares of GlaxoSmithKline in a research report on Friday, May 24th. Finally, Credit Suisse Group set a GBX 1,600 ($20.91) price objective on GlaxoSmithKline and gave the stock a neutral rating in a research report on Wednesday, April 10th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and five have assigned a buy rating to the company’s stock. GlaxoSmithKline currently has an average rating of Hold and a consensus target price of GBX 1,531.41 ($20.01).
GSK stock opened at GBX 1,584.40 ($20.70) on Tuesday. The company has a debt-to-equity ratio of 942.07, a quick ratio of 0.45 and a current ratio of 0.72. GlaxoSmithKline has a 1-year low of GBX 1,408.80 ($18.41) and a 1-year high of GBX 1,648.80 ($21.54). The firm has a market capitalization of $78.38 billion and a price-to-earnings ratio of 20.18.
The company also recently declared a dividend, which will be paid on Thursday, July 11th. Stockholders of record on Thursday, May 16th will be given a dividend of GBX 19 ($0.25) per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a dividend yield of 1.22%. GlaxoSmithKline’s dividend payout ratio is presently 0.97%.
In other news, insider Manvinder Singh Banga purchased 458 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were purchased at an average price of GBX 1,568 ($20.49) per share, with a total value of £7,181.44 ($9,383.82). Insiders have bought a total of 474 shares of company stock worth $742,847 in the last ninety days.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Article: What is channel trading?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.